Novartis agreed to acquire Pikavation Therapeutics—a Synnovation subsidiary—paying $2 billion upfront for a selective, pan‑mutant PI3Kα inhibitor (SNV‑4818) aimed at breast cancer, with up to $1 billion in milestones. The deal is intended to defend Novartis’ PIK3CA-targeted portfolio amid competition to alpelisib (Piqray) and represents a strategic bet on next‑generation PI3Kα agents with improved tolerability and mutant selectivity. Industry sources say the acquisition signals renewed M&A activity around targeted kinase selectors and that big pharma remains willing to pay premium upfronts for de‑risked, clinic‑ready oncology assets. Novartis’ move illustrates the tactical use of bolt-on buys to protect market share and diversify options against late‑stage competitors.